About Medicxi
Medicxi is a Financial Services company based in London (United Kingdom). Early-stage life science focused VC firm investing in geographies such as Europe and the US. It operates on a B2B model. Its focus areas include Investment Industry, Venture Capital Funds, Independent Funds and Conventional VCs.
Company details
Early-stage venture capital investments are provided by Medicxi to life science companies, with a focus on sectors including therapeutics, biopharma, diagnostics, and medical devices. Operations are conducted across Europe and the United States. Portfolio holdings include Genmab, Acutus Medical, Versartis, and CoMentis, reflecting commitments to innovative healthcare technologies and treatments.
- Headquarters London, United Kingdom
- SectorsFinancial Services
- Website medicxi.com
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medicxi
Complete news archive for Medicxi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medicxi
Medicxi is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Early-stage venture capital investments are provided by Medicxi to life science companies, with a focus on sectors including therapeutics, biopharma, diagnostics, and medical devices. Operations are conducted across Europe and the United States. Portfolio holdings include Genmab, Acutus Medical, Versartis, and CoMentis, reflecting commitments to innovative healthcare technologies and treatments.